The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
OPTIMIS: An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).
Markus Peck-Radosavljevic
Consultant or Advisory Role - Bayer Schering Pharma
Honoraria - Bayer Schering Pharma
Research Funding - Bayer Schering Pharma
Jean-Luc Raoul
Consultant or Advisory Role - Bayer Schering Pharma
Honoraria - Bayer Schering Pharma
Han Chu Lee
Research Funding - Bayer
Masatoshi Kudo
No relevant relationships to disclose
Keiko Nakajima
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Ann-Lii Cheng
Consultant or Advisory Role - Boehringer Ingelheim